U.S. markets open in 8 hours
  • S&P Futures

    3,934.25
    -2.50 (-0.06%)
     
  • Dow Futures

    33,620.00
    -5.00 (-0.01%)
     
  • Nasdaq Futures

    11,492.25
    -17.25 (-0.15%)
     
  • Russell 2000 Futures

    1,807.60
    -0.40 (-0.02%)
     
  • Crude Oil

    72.57
    +0.56 (+0.78%)
     
  • Gold

    1,796.80
    -1.20 (-0.07%)
     
  • Silver

    22.84
    -0.08 (-0.34%)
     
  • EUR/USD

    1.0512
    -0.0002 (-0.02%)
     
  • 10-Yr Bond

    3.4080
    0.0000 (0.00%)
     
  • Vix

    22.68
    +0.51 (+2.30%)
     
  • GBP/USD

    1.2196
    -0.0010 (-0.08%)
     
  • USD/JPY

    136.8580
    +0.3340 (+0.24%)
     
  • BTC-USD

    16,808.44
    -191.29 (-1.13%)
     
  • CMC Crypto 200

    394.32
    -7.71 (-1.92%)
     
  • FTSE 100

    7,489.19
    -32.20 (-0.43%)
     
  • Nikkei 225

    27,574.43
    -111.97 (-0.40%)
     

Could The Market Be Wrong About IRadimed Corporation (NASDAQ:IRMD) Given Its Attractive Financial Prospects?

It is hard to get excited after looking at IRadimed's (NASDAQ:IRMD) recent performance, when its stock has declined 26% over the past three months. But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Particularly, we will be paying attention to IRadimed's ROE today.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.

See our latest analysis for IRadimed

How Is ROE Calculated?

Return on equity can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for IRadimed is:

17% = US$10m ÷ US$63m (Based on the trailing twelve months to March 2022).

The 'return' is the profit over the last twelve months. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.17 in profit.

What Has ROE Got To Do With Earnings Growth?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes.

A Side By Side comparison of IRadimed's Earnings Growth And 17% ROE

To begin with, IRadimed seems to have a respectable ROE. Especially when compared to the industry average of 10% the company's ROE looks pretty impressive. This certainly adds some context to IRadimed's decent 17% net income growth seen over the past five years.

We then performed a comparison between IRadimed's net income growth with the industry, which revealed that the company's growth is similar to the average industry growth of 15% in the same period.

past-earnings-growth
past-earnings-growth

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. If you're wondering about IRadimed's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

Is IRadimed Efficiently Re-investing Its Profits?

IRadimed doesn't pay any dividend currently which essentially means that it has been reinvesting all of its profits into the business. This definitely contributes to the decent earnings growth number that we discussed above.

Conclusion

Overall, we are quite pleased with IRadimed's performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. We also studied the latest analyst forecasts and found that the company's earnings growth is expected be similar to its current growth rate. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.